EFFECT OF AVEMARŪ IN PATIENTS OF HIGH RISK MELANOMA

An opened, comparative study

 

Back to Clinical pages Print this page


Center: Melanoma Unit, Department of General Surgery, N.N. Blokhin Cancer Research Center, Moscow, Russia
Principal investigator: Prof. Dr. Demidov, Lev MD, PhD, Professor and Head of Unit
Duration of study: 1999-2001
Number of patients: Avemar Group: 22 pts; Control Group : 24 pts
Mean duration of Avemar treatment: 12 months
All pts had UICC stage III disease
All pts underwent radical surgery, and received dacarbazine (DTIC) chemotherapy.
 

 

Results
 
Occurrence of progression-related events (end-point analysis).

 

 

Avemar (n = 22)

control (n = 24)

 

#

%

#

%

patients with new recurrent disease1

0

0

5

20.1

patients with new metastatic lesions2

5

22.7

17

70.8

deaths

0

0

0

0

overall progression events3

5

22.7

22

91.7

 

 
 
 
 
 
 
1p < 0.001. 2p < 0.001. 3p < 0.001. 
 

 

Conclusions: In terms of disease progression, Avemar treatment plus dacarbazine chemotherapy is superior than dacarbazine chemotherapy alone for high risk melanoma patients.

 

Back to Clinical pages Print this page

 

.       Powered by webEFEKTs.